The DOI matches its Crossref record; 361 of the 361 references it cites were found in a registry or an index.
Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams
Open accessAbstract
Like any other drug, antimicrobial drugs are prone to pharmacokinetic drug interactions. These drug interactions are a major concern in clinical practice as they may have an effect on efficacy and toxicity. This article provides an overview of all published pharmacokinetic studies on drug interactions of the commonly prescribed antimicrobial drugs oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams, focusing on systematic research. We describe drug-food and drug-drug interaction studies in humans, affecting antimicrobial drugs as well as concomitantly administered drugs. Since knowledge about mechanisms is of paramount importance for adequate management of drug interactions, the most plausible underlying mechanism of the drug interaction is provided when available. This overview can be used in daily practice to support the management of pharmacokinetic drug interactions of antimicrobial drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It should be noted that ciprofloxacin is metabolized in the liver and can directly inhibit CYP1A2, CYP2D6, and CYP3A4 (Bolhuis et al., 2011).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Bolhuis et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation
Lau, W. C., Waskell, L. A., Watkins, P. B., Neer, C. J., Horowitz, K., Hopp, A. S., Tait, A. R., Carville, D. G. M., Guyer, K. E., & Bates, E. (2003) · Circulation · doi:10.1161/01.cir.0000047060.60595.cc · Cited by 686
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
A potentially hazardous interaction between erythromycin and midazolam
Olkkola, K. T., Aranko, K., Luurila, H., Hiller, A., Saarnivaara, L., Himberg, J., & Neuvonen, P. J. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.25 · Cited by 351
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90151-5 · Cited by 285
Westphal, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109797 · Cited by 285
Backman, J. T., Kivistö, K. T., Olkkola, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050420 · Cited by 266
Jacobson, T. A. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.07.080 · Cited by 243
Rifampin drastically reduces plasma concentrations and effects of oral midazolam
Backman, J. T., Olkkola, K. T., & Neuvonen, P. J. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90018-1 · Cited by 242
López-Cortés, L. F., Ruiz-Valderas, R., Viciana, P., Alarc??n-Gonz??lez, A., G??mez-Mateos, J., Jiménez, E. M. L., Sarasa-Nacenta, M., L??pez-Pua, Y., & Pach??n, J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241090-00004 · Cited by 227
The effect of rifampin administration on the disposition of fexofenadine
Hamman, M. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113697 · Cited by 204
Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin
Nix, D. E., Watson, W. A., Lener, M. E., et al. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.207 · Cited by 187
Pharmacokinetics of Rifampin Under Fasting Conditions, With Food, and With Antacids
Peloquin, C. A., Namdar, R., Singleton, M. D., et al. (1999) · CHEST Journal · doi:10.1378/chest.115.1.12 · Cited by 179
Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis
Nijland, H. M. J., Ruslami, R., Suroto, A. J., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/521894 · Cited by 167
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations
Kyrklund, C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111414 · Cited by 163
Wenning, L. A., Hanley, W. D., Brainard, D. M., Petry, A. S., Ghosh, K., Jin, B., Mangin, E. C., Marbury, T. C., Berg, J. K., Chodakewitz, J., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01468-08 · Cited by 162
Bolton, A. E., Peng, B., Hubert, M., Krebs‐Brown, A., Capdeville, R., Keller, U., & Seiberling, M. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0722-9 · Cited by 160
Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans
Nakashima, M., Uematsu, T., Kosuge, K., et al. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2635 · Cited by 160
Low Antituberculosis Drug Concentrations in Patients with AIDS
Peloquin, C. A., Nitta, A. T., Burman, W. J., Brudney, K. F., Miranda-Massari, J. R., McGuinness, M. E., Berning, S. E., & Gerena, G. T. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603000901 · Cited by 158
Backman, J. T., Luurila, H., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.04.007 · Cited by 156
Granfors, M. T., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.018 · Cited by 155
Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and Metoprolol
Swaisland, H., Ranson, M., Smith, R. P., Leadbetter, J., Laight, A., McKillop, D., & Wild, M. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00005 · Cited by 154
Rengelshausen, J., Göggelmann, C., Burhenne, J., Riedel, K., Ludwig, J., Weiß, J., Mikus, G., Walter‐Sack, I., & Haefeli, W. E. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01824.x · Cited by 148
P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans
Schwarz, U. I., Gramatté, T., Krappweis, J., et al. (2000) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38161 · Cited by 146
Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers
Hébert, M. F., Fisher, R. M., Marsh, C. L., et al. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922007499 · Cited by 144
Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole*
Kivistö, K. T., Lamberg, T. S., Kantola, T., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90038-2 · Cited by 144
Linezolid absolute bioavailability and the effect of food on oral bioavailability
Welshman, I. R., Sisson, T. L., Jungbluth, G. L., Stalker, D. J., & Hopkins, N. K. (2001) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.255 · Cited by 133
Gustavson, L. E., Kaiser, J., Edmonds, A., et al. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.2078 · Cited by 129
Shishoo, C. J., Shah, S. A., Rathod, I. S., et al. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00831-6 · Cited by 127
Zheng, H., Huang, Y. L., Frassetto, L. A., & Benet, L. Z. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.186 · Cited by 125
Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy
Fost, D. A., Leung, D. Y. M., Martin, R. J., Brown, E. E., Szefler, S. J., & Spahn, J. D. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70175-2 · Cited by 125
Furuta, T., Ohashi, K., Kobayashi, K., et al. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70034-2 · Cited by 121
Interference of dairy products with the absorption of ciprofloxacin
Neuvonen, P. J., Kivistö, K. T., & Lehto, P. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.174 · Cited by 118
Rifampin decreases the plasma concentrations and effects of repaglinide
Niemi, M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111183 · Cited by 115
Methadone, ciprofloxacin, and adverse drug reactions
Herrlin, K., Segerdahl, M., Gustafsson, L. L., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03409-7 · Cited by 115
Nijland, H. M. J., L'homme, R. F., Rongen, G. A. P. J. M., et al. (2008) · AIDS · doi:10.1097/qad.0b013e3282faa71e · Cited by 114
Interaction of Sodium Warfarin and Rifampin
O’Reilly, R. A. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-3-337 · Cited by 114
Serotonin Syndrome and Linezolid
Wigen, C. L., & Goetz, M. B. (2002) · Clinical Infectious Diseases · doi:10.1086/340710 · Cited by 110
Hatorp, V., Hansen, K. T., & Thomsen, M. S. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003253704 · Cited by 109
Clinical and chemical interactions between iron preparations and ciprofloxacin.
Kara, M., Hasinoff, B., McKay, D., & Campbell, N. R. C. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb05526.x · Cited by 107
Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of Moxifloxacin
WEINER, M. H., Burman, W. J., Luo, C.-C., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01621-06 · Cited by 106
Triazolam is ineffective in patients taking rifampin
Villikka, K., Kivistö, K. T., Backman, J. T., Olkkola, K. T., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90176-4 · Cited by 106
Rifampin Greatly Reduces the Plasma Concentrations of Intravenous and Oral Oxycodone
Nieminen, T. H., Hagelberg, N. M., Saari, T. I., Pertovaara, A., Neuvonen, M., Laine, K., Neuvonen, P. J., & Olkkola, K. T. (2009) · Anesthesiology · doi:10.1097/aln.0b013e31819faa54 · Cited by 102
Erythromycin-felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice*
Bailey, D. G., Bend, J. R., Arnold, J. M. O., et al. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90163-0 · Cited by 101
Oxidation of the Novel Oxazolidinone Antibiotic Linezolid in Human Liver Microsomes
Wynalda, M. A., Hauer, M. J., & Wienkers, L. C. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15179-3 · Cited by 101
Gallicano, K., Sahai, J. V., Shukla, V. K., et al. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00987.x · Cited by 100
Potential for Interactions between Caspofungin and Nelfinavir or Rifampin
Stone, J. A., Migoya, E. M., Hickey, L., Winchell, G. A., Deutsch, P., Ghosh, K., Freeman, A., Bi, S., Desai, R., Dilzer, S. C., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4306-4314.2004 · Cited by 99
Effect of Rifampin on the Pharmacokinetics of Rosiglitazone in Healthy Subjects
Park, J. Y., Kim, K., Kang, M., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.003 · Cited by 98
Loboz, K. K., Gross, A. S., WILLIAMS, K., Liauw, W., Day, R. O., Blievernicht, J., Zanger, U. M., & McLachlan, A. J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.010 · Cited by 98
Possible implications of doxycycline-rifampin interaction for treatment of brucellosis
Colmenero, J. D., Fernández-Gallardo, L. C., Agúndez, J. A. G., et al. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.12.2798 · Cited by 93
Effect of probenecid on the distribution and elimination of ciprofloxacin in humans
Jaehde, U., Sörgel, F., Reiter, A., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90173-6 · Cited by 92
Raaska, K., & Neuvonen, P. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000192 · Cited by 91
Cohen, K., Cutsem, G. V., Boulle, A., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm484 · Cited by 91
Interaction between midazolam and clarithromycin: comparison with azithromycin.
Yeates, R. A., Laufen, H., & Zimmermann, T. (1996) · PubMed · Cited by 90
Effect of rifampicin on the pharmacokinetics of pioglitazone
Jaakkola, T., Backman, J. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02515.x · Cited by 89
Yasui, N., Otani, K., Kaneko, S., Ohkubo, T., Osanai, T., Sugawara, K., Chiba, K., & Ishizaki, T. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90179-4 · Cited by 89
Gupta, S., Banfield, C. R., Kantesaria, B. S., Marino, M. T., Clement, R., Affrime, M. B., & Batra, V. K. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80049-7 · Cited by 88
Turck, B. J. D., Diltoer, M., Cornelis, P. J., et al. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.4.563 · Cited by 88
The effect of erythromycin on the pharmacokinetics of rosuvastatin
Cooper, K. J., Martin, P. D., Dane, A. L., Warwick, M. J., Raza, A., & Schneck, D. W. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0573-7 · Cited by 87
Glyburide-ciprofloxacin interaction with resistant hypoglycemia
Roberge, R. J., Kaplan, R. M., Frank, R., et al. (2000) · Annals of Emergency Medicine · doi:10.1067/mem.2000.108617 · Cited by 87
Hendershot, P. E., Antal, E. J., Welshman, I. R., Batts, D. H., & Hopkins, N. K. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010302 · Cited by 86
Abel, S., Jenkins, T. M., Whitlock, L. A., Ridgway, C. E., & Muirhead, G. J. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03134.x · Cited by 86
Hafner, R., Bethel, J., Power, M. E., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.631 · Cited by 85
Krishna, G., Parsons, A. C., Kantesaria, B. S., et al. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167507 · Cited by 85
Pharmacokinetic Interaction Between High-Dose Methotrexate and Amoxycillin
Ronchera, C. L., Hernandez, T., Peris, J., et al. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199310000-00004 · Cited by 85
Naesens, M., Kuypers, D. R. J., Streit, F., Armstrong, V. W., Oellerich, M., Verbeke, K., & Vanrenterghem, Y. F. C. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.08.002 · Cited by 84
Effect of erythromycin on theophylline kinetics
Prince, R. A., Wing, D. S., Weinberger, M. M., et al. (1981) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(81)90196-2 · Cited by 83
Ebert, U., Thong, N. Q., Oertel, R., et al. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000146 · Cited by 83
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide
Bidstrup, T. B., Stilling, N. M., Damkier, P., et al. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0746-z · Cited by 83
Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin
Kays, M. B., Overholser, B. R., Mueller, B. A., et al. (2003) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.08.027 · Cited by 83
Cyclosporin‐erythromycin interaction in renal transplant patients.
Gupta, S., Bakran, A., Johnson, R. W. G., et al. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb05396.x · Cited by 81
Grub, S., Bryson, H., Goggin, T., Lüdin, E., & Jorga, K. M. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100277 · Cited by 81
Pharmacokinetic interaction between rifampin and zidovudine
Burger, D. M., Meenhorst, P. L., Koks, C. H. W., & Beijnen, J. H. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.7.1426 · Cited by 81
Linezolid and Serotonin Syndrome
Lavery, S., Ravi, H., McDaniel, W. W., et al. (2001) · Psychosomatics · doi:10.1176/appi.psy.42.5.432 · Cited by 80
Cations in the didanosine tablet reduce ciprofloxacin bioavailability
Sahai, J. V., Gallicano, K., Oliveras, L., et al. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.24 · Cited by 80
Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide
Lilja, J. J., Niemi, M., Fredrikson, H., et al. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02836.x · Cited by 79
Haas, D. W., Koletar, S. L., Laughlin, L., et al. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318189a7df · Cited by 79
Burger, D. M., Agarwala, S., Child, M., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00461-06 · Cited by 79
Linezolid and rifampin: Drug interaction contrary to expectations?
Egle, H., Trittler, R., Kümmerer, K., et al. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.020 · Cited by 78
Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin
Mueller, B. A., Brierton, D. G., Abel, S. R., et al. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.9.2101 · Cited by 78
Sucralfate significantly reduces ciprofloxacin concentrations in serum
Garrelts, J. C., Godley, P. J., Peterie, J. D., et al. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.5.931 · Cited by 78
Pharmacokinetic Study of Tenofovir Disoproxil Fumarate Combined with Rifampin in Healthy Volunteers
Droste, J. A. H., Wissen, C. P. W. G. M. V.-V., Kearney, B. P., Buffels, R., vanHorssen, P. J., Hekster, Y. A., & Burger, D. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.680-684.2005 · Cited by 78
Effect of Rifampin on Apparent Clearance of Everolimus
Kovarik, J. M., Hartmann, S., Figueiredo, J., et al. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a384 · Cited by 78
The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin.
Lehto, P., Kivistö, K., & Neuvonen, P. J. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04245.x · Cited by 77
Neuhofel, A. L., Wilton, J. H., Victory, J. M., Hejmanowski, L. G., & Amsden, G. W. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011391 · Cited by 77
Acute Seizures Due to a Probable Interaction between Valproic Acid and Meropenem
Coves-Orts, F. J., Borrás‐Blasco, J., Navarro‐Ruiz, A., et al. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e358 · Cited by 76
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects
Kyrklund, C., Backman, J. T., Neuvonen, M., et al. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01972.x · Cited by 75
The Effect of Sucralfate Pretreatment on the Pharmacokinetics of Ciprofloxacin
Nix, D. E., Watson, W. A., Handy, L. M., et al. (1989) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1989.tb04152.x · Cited by 75
A Pharmacokinetic Drug Interaction Between Erythromycin and Triazolam
Phillips, J. P., Antal, E. J., & Smith, R. B. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198610000-00008 · Cited by 75
Altered Pharmacokinetics of Ceftazidime in Critically Ill Patients
Gómez, C. M., Cordingly, J. J., & Palazzo, M. G. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1798 · Cited by 75
Lee, L. J., Hafkin, B., Lee, I. D., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2196 · Cited by 75
The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.
Batty, K. T., Davis, T. M. E., Ilett, K., et al. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04453.x · Cited by 74
Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients
Jaruratanasirikul, S., & Sriwiriyajan, S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050437 · Cited by 72
4-quinolones inhibit biotransformation of caffeine
Harder, S., Staib, A. H., Beer, C., Papenburg, A., Stille, W., & SHAH, P. M. (1988) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637602 · Cited by 72
Healy, D. P., Brodbeck, M., & Clendening, C. E. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.1.6 · Cited by 72
Pharmacokinetic interaction between ritonavir and clarithromycin*
Ouellet, D., Hsu, A., Granneman, G. R., et al. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90065-0 · Cited by 70
Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males
Polk, R. E., Brophy, D. F., Israel, D. S., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.502-508.2001 · Cited by 70
Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide
Park, J. Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00221-2 · Cited by 69
Brannan, M. D., Reidenberg, P., Radwanski, E., Shneyer, L., Lin, C., Cayen, M. N., & Affrime, M. B. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90243-0 · Cited by 69
Azithromycin and terfenadine: Lack of drug interaction*
Harris, S. I., Hilligoss, D. M., Colangelo, P. M., Eller, M. G., & Okerholm, R. A. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90247-3 · Cited by 68
Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis
Ren, Y., Nuttall, J. J. C., Eley, B., et al. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31819c33a3 · Cited by 65
Rifampin reduces plasma concentrations and effects of zolpidem*
Villikka, K., Kivistö, K. T., Luurila, H., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90082-5 · Cited by 64
Semel, J. D., & ALLEN, N. (1991) · Southern Medical Journal · doi:10.1097/00007611-199104000-00013 · Cited by 64
Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate*
Borin, M. T., Chambers, J. H., Carel, B. J., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90134-x · Cited by 63
Lack of Clinically Relevant Interaction Between Desloratadine and Erythromycin
Banfield, C. R., Hunt, T., Reyderman, L., Statkevich, P., Padhi, D., & Affrime, M. B. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241001-00005 · Cited by 62
Depression of theophylline elimination by erythromycin
Renton, K. W., Gray, J. D., & Hung, O. R. (1981) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1981.182 · Cited by 62
Absence of interaction between oxcarbazepine and erythromycin
Keränen, T., Jolkkonen, J., Pk, J., et al. (1992) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1992.tb05051.x · Cited by 62
Justesen, U. S., Andersen, Å. B., Klitgaard, N. A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380794 · Cited by 62
Alffenaar, J. C., Nienhuis, W. A., de Velde, F., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00099-10 · Cited by 62
Self-citationDooley, K. E., Flexner, C. W., Hackman, J., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00554-08 · Cited by 62
Pharmacokinetics of Gatifloxacin and Interaction with an Antacid Containing Aluminum and Magnesium
Lober, S., Ziege, S., Rau, M., et al. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1067 · Cited by 61
Effect of sucralfate on absorption of norfloxacin and ofloxacin
Lehto, P., & Kivistö, K. T. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.2.248 · Cited by 61
Backman, J. T., Granfors, M. T., & Neuvonen, P. J. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0127-x · Cited by 61
Increased Plasma Rifabutin Levels with Concomitant Fluconazole Therapy in HIV-Infected Patients
Trapnell, C. B., Narang, P. K., Li, R., et al. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-6-199603150-00006 · Cited by 61
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride
Niemi, M., Kivistö, K. T., Backman, J. T., et al. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00295.x · Cited by 60
Amsden, G. W., Kuye, O., & Wei, G. C. G. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011373 · Cited by 60
Warfarin and Amoxicillin/Clavulanate Drug Interaction
Davydov, L., Yermolnik, M., & Cuni, L. J. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c243 · Cited by 59
LACK OF A PHARMACOKINETIC INTERACTION BETWEEN AZITHROMYCIN AND CHLOROQUINE
Cook, J., Randinitis, E. J., Bramson, C., et al. (2006) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2006.74.407 · Cited by 59
Epileptic seizures caused by low valproic acid levels from an interaction with meropenem
Fudio, S., Carcas, A. J., Piñana, E., et al. (2006) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2006.00743.x · Cited by 58
Meropenem Decreases Serum Level of Valproic Acid
Nacarküçük, E., Sağlam, H., & Okan, M. (2004) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2004.03.014 · Cited by 57
Foulds, G. H., Luke, D. R., Teng, R., et al. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/37.suppl_c.37 · Cited by 57
SEROTONIN SYNDROME AND LINEZOLID
THOMAS, C. R., Rosenberg, M., Blythe, V., et al. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000128830.13997.aa · Cited by 57
Drug‐Food Interaction Potential of Clarithromycin, A New Macrolide Antimicrobial
Chu, S.-Y., Park, Y., Locke, C. S., et al. (1992) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1992.tb03784.x · Cited by 56
INTERACTION BETWEEN CEPHALOSPORINS AND ALCOHOL
Portier, H., Chalopin, J. M., Freysz, M., et al. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90151-8 · Cited by 56
Matteelli, A., Regazzi, M., Villani, P., et al. (2007) · Current HIV Research · doi:10.2174/157016207780636588 · Cited by 56
Zimmermann, T., Yeates, R. A., Laufen, H., et al. (1996) · PubMed · Cited by 55
Ushiama, H., Echizen, H., Nachi, S., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.125559 · Cited by 55
Terfenadine-associated ventricular arrhythmias and QTc interval prolongation
Hanrahan, J. P., Choo, P. W., Carlson, W., Greineder, D. K., Faich, G. A., & Platt, R. G. (1995) · Annals of Epidemiology · doi:10.1016/1047-2797(94)00039-v · Cited by 55
Effect of Rifampicin on the Pharmacokinetics of Fluconazole in Patients with AIDS
Ayudhya, D. P. N., Thanompuangseree, N., & Tansuphaswadikul, S. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443110-00003 · Cited by 55
Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S‐ketamine
Hagelberg, N. M., Peltoniemi, M. A., Saari, T. I., Kurkinen, K. J., Laine, K., Neuvonen, P. J., & Olkkola, K. T. (2009) · European Journal of Pain · doi:10.1016/j.ejpain.2009.10.003 · Cited by 55
Effect of the Treatment Period With Erythromycin on Cytochrome P450 3A Activity in Humans
Okudaira, T., Kotegawa, T., Imai, H., Tsutsumi, K., Nakano, S., & Ohashi, K. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007302562 · Cited by 54
Dickinson, L., Khoo, S., & Back, D. J. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3282f82bf1 · Cited by 53
Effect of Grapefruit Juice on Clarithromycin Pharmacokinetics
Cheng, K. C., Nafziger, A. N., Peloquin, C. A., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.927 · Cited by 52
Concentrations and effects of buspirone are considerably reduced by rifampicin
Lamberg, T. S., Kivistö, K. T., & Neuvonen, P. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.t01-1-00698.x · Cited by 51
Ki-Seung, L. E. E., Shin, J., Chong, W. S., et al. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315399 · Cited by 51
Zarychanski, R. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl196 · Cited by 51
Serotonin syndrome due to co-administration of linezolid and venlafaxine
Jones, S. L. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh257 · Cited by 51
Interaction between midazolam and clarithromycin in the elderly
Quinney, S. K., Haehner, B. D., Rhoades, M., et al. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02970.x · Cited by 51
Probenecid: an unexplained effect on cephalosporin pharmacology.
Welling, P. G., Dean, S., Selen, A., et al. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb01032.x · Cited by 50
Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine
Isohanni, M. H., Neuvonen, P. J., Palkama, V. J., et al. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050513 · Cited by 49
Boni, J. P., Leister, C. A., Burns, J., Cincotta, M., Hug, B. A., & Moore, L. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007306957 · Cited by 49
Mahatthanatrakul, W., Nontaput, T., Ridtitid, W., et al. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00811.x · Cited by 49
Absence of interaction between erythromycin and a single dose of clozapine
Hägg, S., Spigset, O., Mjörndal, T., et al. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050621 · Cited by 48
Lee, J., Franz, L., & Goforth, H. W. (2009) · Psychosomatics · doi:10.1016/s0033-3182(09)70868-0 · Cited by 48
Gentamicin inactivation by piperacillin or carbenicillin in patients with end-stage renal disease
Thompson, M. I., Russo, M. E., Saxon, B. J., et al. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.21.2.268 · Cited by 48
Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers
Ridtitid, W., Wongnawa, M., Mahatthanatrakul, W., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129319 · Cited by 48
Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid
Landersdorfer, C. B., Kirkpatrick, C. M. J., Kinzig, M., Bulitta, J. B., Holzgrabe, U., Jaehde, U., Reiter, A., Naber, K. G., Rodamer, M., & Sörgel, F. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03564.x · Cited by 48
Sekar, V. J., Lavreys, L., de Casteele, T. V., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01749-09 · Cited by 48
Pharmacokinetic Interaction between Amprenavir and Clarithromycin in Healthy Male Volunteers
Brophy, D. F., Israel, D. S., Pastor, A., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.978-984.2000 · Cited by 48
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects
Niemi, M., Backman, J. T., Neuvonen, M., et al. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01884.x · Cited by 47
A Pharmacokinetic Evaluation of Concomitant Administration of Linezolid and Aztreonam
Sisson, T. L., Jungbluth, G. L., & Hopkins, N. K. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922011962 · Cited by 47
Effects of clarithromycin on lansoprazole pharmacokinetics betweenCYP2C19genotypes
Saito, M., Yasui‐Furukori, N., Uno, T., et al. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02329.x · Cited by 47
Staß, H., ttcher, M.-F. B., & Ochmann, K. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140001-00006 · Cited by 47
Shah, A., Liu, M.-C., Vaughan, D. P., et al. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.suppl_1.49 · Cited by 47
Effects of Lanthanum Carbonate on the Absorption and Oral Bioavailability of Ciprofloxacin
How, P., Fischer, J. H., Arruda, J. A. L., et al. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01580407 · Cited by 47
Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin*
Kivistö, K. T., Villikka, K., Nyman, L. M., Anttila, M. I., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90055-8 · Cited by 47
Pai, M. P., Allen, S. E., & Amsden, G. W. (2006) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2006.01.003 · Cited by 46
Pharmacokinetic variability of zidovudine in HIV-infected individuals
Burger, D. M., Meenhorst, P. L., ten Napel, C. H. H., et al. (1994) · AIDS · doi:10.1097/00002030-199412000-00007 · Cited by 46
Adverse Effect of Rifampin on Quinine Efficacy in Uncomplicated Falciparum Malaria
Pukrittayakamee, S., Prakongpan, S., Wanwimolruk, S., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1509-1513.2003 · Cited by 46
Pharmacokinetic interaction between valproic acid and meropenem
Clause, D., Decleire, P.-Y., Vanbinst, R., et al. (2005) · Intensive Care Medicine · doi:10.1007/s00134-005-2695-0 · Cited by 46
Lack of Enzyme‐Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide
Boyd, M. A., Zhang, X., Dorr, A. E., et al. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003259220 · Cited by 46
Ribera, E., Pou, L., Solà, A. F., Campos, F., López, R. M., Ocaña, I., Ruíz-Camps, I., & Pahissa, A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3238-3241.2001 · Cited by 46
Pharmacokinetic Interaction Between High-Dose Methotrexate and Oxacillin
Titier, K., Lagrange, F., Péhourcq, F., et al. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200208000-00018 · Cited by 46
Letsas, Κ. P., Sideris, A., Kounas, S. P., Efremidis, M., Korantzopoulos, P. G., & Kardaras, F. G. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.04.031 · Cited by 45
Amsden, G. W., Nafziger, A. N., Foulds, G. H., et al. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001226 · Cited by 44
Apseloff, G., Foulds, G. H., LaBoy‐Goral, L., Willavize, S. A., & Vincent, J. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb00017.x · Cited by 43
Steady‐state pharmacokinetic interaction of modified‐dose indinavir and rifabutin
Hamzeh, F. M., Benson, C. A., Gerber, J. G., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.3 · Cited by 43
Serotonin Syndrome after Concomitant Treatment with Linezolid and Meperidine
Das, P. K., Warkentin, D. I., Hewko, R., & Forrest, D. L. (2007) · Clinical Infectious Diseases · doi:10.1086/524671 · Cited by 43
Seizure Worsening Caused by Decreased Serum Valproate During Meropenem Therapy
Santucci, M., Parmeggiani, A., & Riva, R. (2005) · Journal of Child Neurology · doi:10.1177/08830738050200051401 · Cited by 42
Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline.
Robson, R., Begg, E., Atkinson, H., et al. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03669.x · Cited by 42
Refractory Hypoglycemia from Ciprofloxacin and Glyburide Interaction
Lin, G., Hays, D. P., & Spillane, L. L. (2004) · Journal of Toxicology Clinical Toxicology · doi:10.1081/clt-120037431 · Cited by 42
Pentikis, H. S., Connolly, M., Trapnell, C. B., Forbes, W. P., & Bettenhausen, D. K. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.10.1361 · Cited by 41
The Effect of Erythromycin and Fluvoxamine on the Pharmacokinetics of Intravenous Lidocaine
Olkkola, K. T., Isohanni, M. H., Hamunen, K., et al. (2005) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000148123.79437.f9 · Cited by 41
Deng, S., Chen, X., Cao, D., Yin, T., Dai, Z.-Y., Luo, J., Tang, L., & Li, Y. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.06.006 · Cited by 41
Calabresi, L. (2003) · Pharmacological Research · doi:10.1016/j.phrs.2003.10.010 · Cited by 41
Meropenem –valproic acid interaction in patients with cefepime-associated status epilepticus
Spriet, I., Meersseman, W., Troy, E. D., et al. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050512 · Cited by 41
Effect of multiple-dose erythromycin on everolimus pharmacokinetics
Kovarik, J. M., Beyer, D., Bizot, M. N., et al. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0866-5 · Cited by 41
Wallace, A. W., Victory, J. M., & Amsden, G. W. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003253399 · Cited by 41
Tahir, N. (2004) · Journal of the American Medical Directors Association · doi:10.1016/s1525-8610(04)70065-1 · Cited by 40
Kivistö, K. T., Lamberg, T. S., & Neuvonen, P. J. (1999) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1999.tb00880.x · Cited by 40
Borin, M. T., Chambers, J. H., Carel, B. J., et al. (1997) · Antiviral Research · doi:10.1016/s0166-3542(97)00011-9 · Cited by 40
Amsden, G. W., Gregory, T., MICHALAK, C. A., et al. (2007) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.76.1153 · Cited by 40
Combined Use of Ciprofloxacin and Sucralfate
Slooten, A. D. V., Nix, D. E., Wilton, J. H., et al. (1991) · DICP · doi:10.1177/106002809102500601 · Cited by 40
Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans
Sano, M., KAWAKATSU, K., Ohkita, C., et al. (1988) · European Journal of Clinical Pharmacology · doi:10.1007/bf00609246 · Cited by 39
Concentrations and effects of zopiclone are greatly reduced by rifampicin
Villikka, K., Kivistö, K. T., Lamberg, T. S., et al. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00579.x · Cited by 39
Skerjanec, A., Wang, J., Maren, K., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009340418 · Cited by 39
Serotonin Syndrome Associated With Linezolid Treatment After Discontinuation of Fluoxetine
Morales, N., & Vermette, H. (2005) · Psychosomatics · doi:10.1176/appi.psy.46.3.274 · Cited by 39
Zhang, W., Deng, S., Chen, X., Zhou, G., Xie, H., He, F.-Y., Cao, D., Li, Y., & Zhou, H. (2008) · Clinical Therapeutics · doi:10.1016/s0149-2918(08)80052-5 · Cited by 39
Levofloxacin and Ciprofloxacin Decrease Procainamide andN-Acetylprocainamide Renal Clearances
Bauer, L. A., Black, D. J., LIll, J. S., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1649-1651.2005 · Cited by 38
A pharmacokinetic interaction between roxithromycin and midazolam
Backman, J. T., Aranko, K., Himberg, J., & Olkkola, K. T. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00196114 · Cited by 38
Trapnell, C. B., Connolly, M., Pentikis, H. S., Forbes, W. P., & Bettenhausen, D. K. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h395 · Cited by 38
Jordan, M. K., Polis, M. A., Kelly, G., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2170-2172.2000 · Cited by 37
Inhibition of flucloxacillin tubular renal secretion by piperacillin
Landersdorfer, C. B., Kirkpatrick, C. M. J., Kinzig, M., Bulitta, J. B., Holzgrabe, U., & Sörgel, F. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03266.x · Cited by 37
Effect of Telithromycin on the Pharmacokinetics and Pharmacodynamics of Oral Oxycodone
Grönlund, J., Saari, T. I., Hagelberg, N. M., Martikainen, I. K., Neuvonen, P. J., Olkkola, K. T., & Laine, K. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009336444 · Cited by 37
Carr, R. A., Edmonds, A., Shi, H. H., Locke, C. S., Gustavson, L. E., Craft, J. C., Harris, S. I., & Palmer, R. N. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1176 · Cited by 37
Chiu, L. M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg003 · Cited by 37
Loi, C., Parker, B. M., Cusack, B. J., & Vestal, R. E. (1997) · PubMed · Cited by 37
Amoxicillin/clavulanic acid‐warfarin drug interaction: a randomized controlled trial
Zhang, Q., Simoneau, G., Verstuyft, C., et al. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03824.x · Cited by 36
Staß, H., Schühly, U., ller, J.-G. M., et al. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140001-00007 · Cited by 36
The Effects of Erythromycin on Theophylline Elimination in Normal Males
May, D. C., Jarboe, C. H., Ellenburg, D. T., et al. (1982) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1982.tb02659.x · Cited by 36
Elsherbiny, D. A., Cohen, K., Jansson, B., et al. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0481-y · Cited by 35
Research works printed but not linked: 1
- Stockley, I. (2011). Stockley's Drug Interactions, Pharmaceutical Press. [6th ed.].
Cited by
Sorted by citations
Gut reactions: Breaking down xenobiotic–microbiome interactions
Clarke, G., Sandhu, K. V., Griffin, B. T., Dinan, T. G., Cryan, J. F., & Hyland, N. P. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015768 · Cited by 319
Metadata
- Authors
- Bolhuis, M. S., Panday, P. N., Pranger, A. D., Kosterink, J. G. W., & Alffenaar, J.-W. C.
- Affiliations
- University Medical Center Groningen (NL)
- Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
- Corresponding author
- Bolhuis, Mathieu S.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2011-11-18
- Volume
- 3
- Issue
- 4
- Pages
- 865-913
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC3857062
- OpenAlex
- W2151599229
- Cited by
- 62
- References
- 361
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 8 · 2023: 5 · 2022: 9 · 2021: 4 · 2020: 12 · 2019: 6 · 2018: 2 · 2017: 5 · 2015: 2 · 2014: 3
- FWCI
- 0.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- pharmacokinetic interactions, antimicrobial agents, oxazolidinones, macrolides, fluoroquinolones, beta-lactam antibiotics, food-drug interactions, drug-drug interactions, interaction mechanisms, drug efficacy and toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review